Luxembourg vs Netherlands: Prevalence rate of hypertension in adults aged 30-79
Luxembourg
30.5
in 2019
Netherlands
30.5
in 2019
Luxembourg rank
160th
Netherlands rank
160th
Prevalence rate of hypertension in adults aged 30-79 over time
- Luxembourg
- Netherlands
How they compare
Luxembourg currently reports 30.5 against 30.5 in Netherlands, a difference of 0.
The two have swapped places 1 time across 30 shared years of data; in 1990 it was Luxembourg ahead.
Luxembourg ranks 160th and Netherlands ranks 160th of 194 countries.
Luxembourg has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Luxembourg | Netherlands | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 40.5 | 30.36 | 10.14 | Luxembourg |
| 2000s | 39.42 | 35.52 | 3.9 | Luxembourg |
| 2010s | 33.98 | 33.24 | 0.74 | Luxembourg |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of hypertension in adults aged 30-79, Luxembourg or Netherlands?
- Luxembourg, at 30.5 against 30.5 in Netherlands as of 2019.
- What is the difference in prevalence rate of hypertension in adults aged 30-79 between Luxembourg and Netherlands?
- 0, with Luxembourg ahead.
- How many years of comparable data are there for Luxembourg and Netherlands?
- 30 years are reported by both, from 1990 to 2019.
- How do Luxembourg and Netherlands rank globally for prevalence rate of hypertension in adults aged 30-79?
- Luxembourg ranks 160th and Netherlands ranks 160th of 194 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Prevalence rate of hypertension in adults aged 30-79. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated share of the population with hypertension, based on population representative surveys and statistical modeling. Hypertension is a risk factor for chronic complications, including cardiovascular disease, and premature death.